imipenem 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring	1426	64221-86-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: imipenem tienamycin imipemide imipenen imipenem hydrate	Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor. Molecular weight: 299.35 Formula: C12H17N3O4S CLOGP: -0.39 LIPINSKI: 0 HAC: 7 HDO: 4 TPSA: 113.72 ALOGS: -2.64 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

imipenem
tienamycin
imipemide
imipenen
imipenem hydrate

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Molecular weight: 299.35
Formula: C12H17N3O4S
CLOGP: -0.39
LIPINSKI: 0
HAC: 7
HDO: 4
TPSA: 113.72
ALOGS: -2.64
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	P
2	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	69 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	222.82 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.86 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.95 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company
June 23, 2021	PMDA	MSD K.K.
Feb. 13, 2020	EMA	Merck Sharp & Dohme B.V.
Nov. 26, 1985	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	127.59	25.01	92	4431	132542	63351957
Multiple organ dysfunction syndrome	95.53	25.01	56	4467	56696	63427803
Drug resistance	92.94	25.01	41	4482	22892	63461607
Pathogen resistance	67.70	25.01	23	4500	6375	63478124
Septic shock	65.70	25.01	47	4476	66582	63417917
Sepsis	50.07	25.01	58	4465	153065	63331434
Renal failure	49.68	25.01	51	4472	117601	63366898
Eosinophilic pneumonia acute	48.02	25.01	10	4513	416	63484083
Geotrichum infection	46.95	25.01	10	4513	464	63484035
Clostridium difficile colitis	44.63	25.01	24	4499	20545	63463954
Aspergillus infection	44.55	25.01	18	4505	8075	63476424
Aplasia	43.84	25.01	15	4508	4244	63480255
Hepatic infarction	43.36	25.01	10	4513	670	63483829
Rash maculo-papular	39.71	25.01	26	4497	31870	63452629
Deafness	39.09	25.01	21	4502	17936	63466563
Hepatotoxicity	36.18	25.01	26	4497	37015	63447484
Respiratory failure	35.66	25.01	40	4483	101818	63382681
Drug reaction with eosinophilia and systemic symptoms	33.62	25.01	24	4499	33812	63450687
Acute kidney injury	33.51	25.01	64	4459	263351	63221148
Pyrexia	32.77	25.01	90	4433	470388	63014111
Eosinophilia	31.91	25.01	20	4503	22736	63461763
Ototoxicity	31.88	25.01	9	4514	1353	63483146
Granulomatosis with polyangiitis	31.44	25.01	10	4513	2255	63482244
Candida infection	30.23	25.01	21	4502	28330	63456169
Toxic epidermal necrolysis	29.95	25.01	20	4503	25314	63459185
Pain	29.90	25.01	8	4515	740620	62743879
Generalised tonic-clonic seizure	29.79	25.01	21	4502	28995	63455504
Type IV hypersensitivity reaction	29.02	25.01	10	4513	2888	63481611
Thrombocytopenia	28.82	25.01	44	4479	151113	63333386
Drug level below therapeutic	27.39	25.01	11	4512	4855	63479644
Fungaemia	26.84	25.01	9	4514	2394	63482105
Acinetobacter infection	26.21	25.01	8	4515	1575	63482924
Enterococcal infection	25.37	25.01	12	4511	7836	63476663

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	127.93	20.19	111	6661	76455	34873704
Septic shock	127.88	20.19	108	6664	71726	34878433
Drug resistance	117.12	20.19	69	6703	25858	34924301
Pathogen resistance	110.63	20.19	48	6724	9434	34940725
Drug ineffective	104.40	20.19	254	6518	456497	34493662
Eosinophilia	98.44	20.19	62	6710	26160	34923999
Hepatic cytolysis	74.54	20.19	42	6730	14454	34935705
Pseudomonas infection	72.26	20.19	39	6733	12343	34937816
Ototoxicity	68.20	20.19	22	6750	1895	34948264
Candida infection	64.24	20.19	41	6731	17674	34932485
Rash maculo-papular	61.53	20.19	48	6724	28403	34921756
Thrombocytopenia	58.82	20.19	107	6665	156140	34794019
Seizure	58.74	20.19	86	6686	104771	34845388
Drug reaction with eosinophilia and systemic symptoms	43.54	20.19	42	6730	32970	34917189
Acute respiratory distress syndrome	41.93	20.19	37	6735	25932	34924227
Botulism	41.48	20.19	9	6763	162	34949997
Treatment failure	41.26	20.19	48	6724	46649	34903510
Electrocardiogram QT prolonged	41.14	20.19	45	6727	40907	34909252
Geotrichum infection	41.08	20.19	11	6761	493	34949666
Vascular pseudoaneurysm thrombosis	38.43	20.19	7	6765	48	34950111
Brain abscess	37.01	20.19	16	6756	3109	34947050
Fungaemia	36.61	20.19	15	6757	2553	34947606
Splenic candidiasis	35.81	20.19	7	6765	73	34950086
Respiratory failure	35.38	20.19	70	6702	108502	34841657
Bronchopulmonary aspergillosis	34.45	20.19	26	6746	14633	34935526
Nocardiosis	33.42	20.19	16	6756	3935	34946224
Toxic epidermal necrolysis	33.27	20.19	30	6742	21616	34928543
Disseminated intravascular coagulation	33.07	20.19	30	6742	21786	34928373
Cardiac valve vegetation	32.05	20.19	9	6763	482	34949677
Leukocytosis	30.56	20.19	30	6742	24035	34926124
Fatigue	30.54	20.19	17	6755	370636	34579523
Enterococcal infection	29.96	20.19	20	6752	9286	34940873
Graft versus host disease	27.65	20.19	20	6752	10549	34939610
Rash morbilliform	27.64	20.19	13	6759	3074	34947085
Condition aggravated	26.88	20.19	90	6682	192106	34758053
Venoocclusive disease	25.44	20.19	12	6760	2855	34947304
Acoustic neuroma	25.34	20.19	6	6766	162	34949997
Functional gastrointestinal disorder	25.05	20.19	11	6761	2220	34947939
Fusarium infection	24.44	20.19	9	6763	1151	34949008
Sepsis	24.17	20.19	79	6693	166482	34783677
Haemoperitoneum	23.85	20.19	10	6762	1802	34948357
Anuria	23.48	20.19	18	6754	10367	34939792
Ecthyma	23.46	20.19	7	6765	465	34949694
Shock	23.28	20.19	26	6746	24153	34926006
Pulmonary physical examination abnormal	22.42	20.19	4	6768	24	34950135
Pain	22.40	20.19	6	6766	204669	34745490
Benign soft tissue neoplasm	21.80	20.19	5	6767	117	34950042
Product use in unapproved indication	21.02	20.19	60	6712	117439	34832720
Clostridium difficile colitis	20.70	20.19	20	6752	15710	34934449
Bacterial toxaemia	20.67	20.19	5	6767	148	34950011
Embolic cerebral infarction	20.61	20.19	7	6765	707	34949452

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	221.52	20.40	159	10568	120087	79613574
Drug resistance	198.72	20.40	102	10625	42111	79691550
Septic shock	180.75	20.40	142	10585	122659	79611002
Pathogen resistance	179.95	20.40	69	10658	14273	79719388
Eosinophilia	129.68	20.40	79	10648	45266	79688395
Drug ineffective	122.43	20.40	369	10358	1080544	78653117
Seizure	121.55	20.40	138	10589	188696	79544965
Ototoxicity	97.12	20.40	30	10697	3244	79730417
Pseudomonas infection	96.83	20.40	50	10677	20853	79712808
Thrombocytopenia	90.34	20.40	142	10585	265117	79468544
Rash maculo-papular	89.23	20.40	68	10659	56010	79677651
Candida infection	87.82	20.40	58	10669	38156	79695505
Geotrichum infection	85.62	20.40	21	10706	960	79732701
Hepatic cytolysis	79.39	20.40	48	10679	27103	79706558
Respiratory failure	68.79	20.40	102	10625	180809	79552852
Drug reaction with eosinophilia and systemic symptoms	66.98	20.40	61	10666	64183	79669478
Sepsis	65.13	20.40	124	10603	269304	79464357
Renal failure	58.09	20.40	100	10627	200868	79532793
Electrocardiogram QT prolonged	57.94	20.40	66	10661	90320	79643341
Toxic epidermal necrolysis	57.92	20.40	48	10679	44533	79689128
Pain	56.18	20.40	13	10714	703789	79029872
Fatigue	54.11	20.40	29	10698	929698	78803963
Bronchopulmonary aspergillosis	54.05	20.40	35	10692	22259	79711402
Leukocytosis	52.76	20.40	45	10682	43410	79690251
Enterococcal infection	51.83	20.40	30	10697	15630	79718031
Clostridium difficile colitis	51.01	20.40	39	10688	32244	79701417
Acute respiratory distress syndrome	48.20	20.40	43	10684	44024	79689637
Nocardiosis	46.08	20.40	20	10707	5659	79728002
Aspergillus infection	43.80	20.40	29	10698	19132	79714529
Treatment failure	41.79	20.40	79	10648	170407	79563254
Acinetobacter infection	40.78	20.40	15	10712	2762	79730899
Vascular pseudoaneurysm thrombosis	40.25	20.40	7	10720	54	79733607
Disseminated intravascular coagulation	39.24	20.40	35	10692	35807	79697854
Brain abscess	38.80	20.40	17	10710	4919	79728742
Headache	38.54	20.40	20	10707	653752	79079909
Splenic candidiasis	38.18	20.40	7	10720	75	79733586
Arthralgia	37.58	20.40	15	10712	571788	79161873
Botulism	37.34	20.40	9	10718	382	79733279
Generalised tonic-clonic seizure	36.84	20.40	37	10690	43873	79689788
Eosinophilic pneumonia acute	36.57	20.40	11	10716	1087	79732574
Klebsiella infection	36.44	20.40	24	10703	15696	79717965
Shock	35.27	20.40	36	10691	43512	79690149
Hepatic infarction	34.10	20.40	10	10717	905	79732756
Agranulocytosis	32.49	20.40	35	10692	44995	79688666
Fall	31.68	20.40	13	10714	487616	79246045
Fungaemia	30.32	20.40	14	10713	4577	79729084
Graft versus host disease	30.20	20.40	21	10706	15005	79718656
Cardiac valve vegetation	29.72	20.40	9	10718	910	79732751
Rash morbilliform	29.30	20.40	15	10712	6135	79727526
Pyrexia	29.19	20.40	173	10554	678536	79055125
Nephropathy toxic	28.64	20.40	23	10704	20396	79713265
Systemic candida	28.08	20.40	15	10712	6691	79726970
Product use in unapproved indication	27.50	20.40	85	10642	250274	79483387
Hepatotoxicity	27.13	20.40	34	10693	51318	79682343
Pancytopenia	26.93	20.40	65	10662	165680	79567981
Staphylococcal infection	26.75	20.40	36	10691	58259	79675402
Pain in extremity	26.61	20.40	8	10719	364530	79369131
Off label use	26.39	20.40	210	10517	907005	78826656
Acute kidney injury	26.02	20.40	138	10589	519266	79214395
Aplasia	25.92	20.40	15	10712	7805	79725856
Gamma-glutamyltransferase increased	25.44	20.40	34	10693	54646	79679015
Hepatic failure	25.38	20.40	36	10691	61176	79672485
Toxic skin eruption	24.86	20.40	22	10705	22271	79711390
Abscess	24.31	20.40	22	10705	22929	79710732
HIV infection	23.88	20.40	8	10719	1119	79732542
Pulmonary physical examination abnormal	23.88	20.40	4	10723	24	79733637
Acoustic neuroma	23.84	20.40	6	10721	305	79733356
Dermatitis exfoliative	23.81	20.40	16	10711	10813	79722848
Abdominal discomfort	23.51	20.40	3	10724	250724	79482937
Benign soft tissue neoplasm	23.22	20.40	5	10722	127	79733534
Heparin-induced thrombocytopenia	22.97	20.40	15	10712	9667	79723994
Granulomatosis with polyangiitis	22.93	20.40	10	10717	2860	79730801
Drug level below therapeutic	22.85	20.40	15	10712	9755	79723906
Encephalopathy	22.74	20.40	36	10691	67361	79666300
Organ failure	22.65	20.40	11	10716	4022	79729639
Hypoproteinaemia	22.62	20.40	11	10716	4035	79729626
Type IV hypersensitivity reaction	22.53	20.40	11	10716	4070	79729591
Stevens-Johnson syndrome	22.41	20.40	27	10700	39139	79694522
Weight increased	22.31	20.40	5	10722	277381	79456280
Bacterial toxaemia	22.17	20.40	5	10722	158	79733503
Cholestasis	22.12	20.40	31	10696	52078	79681583
Deafness	21.95	20.40	20	10707	21017	79712644
Back pain	21.61	20.40	7	10720	304173	79429488
Peripheral swelling	21.41	20.40	5	10722	269612	79464049
Venoocclusive disease	21.34	20.40	11	10716	4562	79729099
Candida sepsis	20.88	20.40	9	10718	2504	79731157
Myoclonus	20.83	20.40	22	10705	27638	79706023
Functional gastrointestinal disorder	20.44	20.40	11	10716	4979	79728682
Intracardiac mass	20.44	20.40	5	10722	226	79733435

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DH51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
ATC	J01DH56	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bacterial septicemia	indication	10001005	DOID:0040085
Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs	indication	11218009
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Pneumonia due to Streptococcus	indication	34020007
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Haemophilus influenzae pneumonia	indication	70036007
Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs	indication	71057007
Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs	indication	71120004
Abdominal abscess	indication	75100008
Endometritis	indication	78623009	DOID:1002
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial endocarditis	indication	301183007
Bacterial urinary infection	indication	312124009
Infectious disorder of joint	indication	363162000
Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs	indication	406574007
Acute exacerbation of chronic bronchitis	indication	425748003
Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs	indication	840588006
Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs	indication	1137353009
Gram-Negative Aerobic Bacillary Pneumonia	indication
Enterobacter Pneumonia	indication
Diabetic Foot Infection	indication
Inflammatory Disease of Female Pelvic Organs	indication
Pyrexia of unknown origin	off-label use	7520000
Inhalational anthrax	off-label use	11389007
Cutaneous anthrax	off-label use	84980006	DOID:7426
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Infection by Campylobacter fetus	off-label use	111835002
Gas gangrene caused by clostridium perfringens	off-label use	266093005
Anthrax	off-label use	409498004	DOID:7427
Melioidosis	off-label use	428111003	DOID:5052
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Clostridium Perfringens Empyema	off-label use
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Lesion of brain	contraindication	301766008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.9	acidic
pKa2	9.92	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	8487093	Nov. 19, 2029	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2024	NEW CHEMICAL ENTITY
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	RECARBRIO	MSD MERCK CO	N212819	July 16, 2019	RX	POWDER	INTRAVENOUS	July 16, 2029	GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme	PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 4	Enzyme	Q5D1E9_STAAU		IC50	7.30	WOMBAT-PK
Penicillin-binding protein 1	Enzyme	A1KS91_NEIMF		IC50	7	WOMBAT-PK
Beta-lactamase	Enzyme	A2RP81_CITFR		Ki	7.22	CHEMBL
Beta-lactamase GES-13	Enzyme	D1MIX9_PSEAI		IC50	6.82	CHEMBL

External reference:

ID	Source
4017969	VUID
N0000146319	NUI
D00206	KEGG_DRUG
4017969	VANDF
C0020933	UMLSCUI
CHEBI:51799	CHEBI
ID1	PDB_CHEM_ID
CHEMBL43708	ChEMBL_ID
CHEMBL148	ChEMBL_ID
DB01598	DRUGBANK_ID
D015378	MESH_DESCRIPTOR_UI
104838	PUBCHEM_CID
10821	IUPHAR_LIGAND_ID
71OTZ9ZE0A	UNII
5690	RXNORM
4869	MMSL
d04401	MMSL
002813	NDDF
424285002	SNOMEDCT_US
46558003	SNOMEDCT_US
74431-23-5	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3514	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3514	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3516	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3516	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3551	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3551	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3552	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
PRIMAXINIV	HUMAN PRESCRIPTION DRUG LABEL	2	0006-3552	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	25 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-322	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections
Imipenem and Cilastatin	HUMAN PRESCRIPTION DRUG LABEL	2	63323-349	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	26 sections